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ABSTRACT: Previous studies have shown that chorioamnionitis,
with increased IL-6, promotes fetal lung maturation and decreases the
incidence of respiratory distress syndrome in premature neonates.
However, the expression pattern and the effects of IL-6 on fetal lung
growth mechanisms remain unknown. IL-6 expression was assessed
by in situ hybridization and by real-time PCR between 14.5 and
21.5 d postconception. Normal and nitrofen-induced hypoplastic lung
explants were cultured with increasing IL-6 doses or IL-6 neutraliz-
ing antibodies. Branching, cellular proliferation (Ki-67) and MAPK
phosphorylation in fetal lung explants were analyzed. Pulmonary
primitive epithelium expressed IL-6 constitutively throughout all
gestational ages, displaying highest levels during earliest stages. In
normal and hypoplastic lung explants, IL-6 neutralizing antibodies
significantly reduced, whereas IL-6 supplementation induced a bi-
phasic effect (lower doses increased, while the highest dose did not
accomplish additional effect) on branching and cellular proliferation.
IL-6 enhanced p38-MAPK phosphorylation without changing
MEK1/2 and JNK pathways. The present study suggests a physio-
logical role for IL-6 on pulmonary branching mechanisms most
likely involving p38-MAPK intracellular signalling pathway. (Pe-
diatr Res 60: 530–536, 2006)
During the last decades, the regulating mechanisms of lungbranching have been unraveled. This morphogenic pro-
cess occurs through fundamental cross-talk interactions be-
tween epithelial and mesenchymal tissues via extremely com-
plex processes, involving a multitude of effectors including
growth factors, extracellular matrix interactions, and hormones
(1). The understanding of these mechanisms has clinical rele-
vance since it can open new perspectives in the treatment of fetal
lung hypoplasia as well as modulation of lung repair.
IL-6 is a pleiotropic cytokine with important roles on acute
inflammatory response, infection, hematopoiesis, regulation of
bone absorption, cell growth, differentiation, survival, apopto-
sis, and proliferation (2–4). Several studies have emphasized
the importance of IL-6 signaling in several processes of
branching organs such as embryonic submandibular gland
development (5,6), mammary gland remodeling (7), benign
and malign prostate growth (8,9), and lung maturation (10).
In fact, several clinical and animal-based studies suggest
that antenatal exposure to inflammatory mediators may im-
prove lung volume and compliance as well as accelerate fetal
lung maturation (10). In humans, it was demonstrated that
IL-6 elevation in fetuses with chorioamnionitis promoted fetal
lung maturation by enhancing surfactant protein A (SP-A)
synthesis. In fact, fetal IL-6 is a regulatory cytokine of pul-
monary surfactant proteins and plays an important role in lung
maturity decreasing the incidence of respiratory distress syn-
drome in preterm neonates (11). In different animal models
such as the rat (12), the rabbit (10), and the sheep (13), it was
shown that intra-amniotic injection of endotoxin or continuous
administration of IL-6 improved lung function by increasing
expression of surfactant apoprotein mRNA (12,14,15).
Recently, it was demonstrated that IL-6 plays an important
modulatory role in lung angiogenesis (16), a fundamental
process in fetal lung morphogenesis (17). Moreover, Dame
and Juul (4) demonstrated that IL-6 receptor was widely
distributed in developing human fetuses, including in bron-
chial epithelial cells. Such findings suggest an IL-6 nonhema-
topoietic role in the developing fetus.
IL-6 exerts its action via the signal transducer gp130 lead-
ing to the activation of the JAK/STAT (Janus kinase/signal
transducer and activator of transcription) and MAPK cascades
(2). Many of the effectors that modulate fetal lung branching
morphogenesis seem to activate signaling pathways that con-
verge into the mitogen-activated protein MAPK (18). There
are three major families of MAPK: the extracellular signal-
regulated kinases-1 and -2 (ERK1/2), c-Jun NH2-terminal
kinases (JNK), and p38 kinase.
Although several reports demonstrated that IL-6 can mod-
ulate lung development, the IL-6 expression pattern as well as
its effects during early lung development are largely unknown.
Therefore, in the current study, IL-6 expression during ante-
natal lung development was characterized. Furthermore, the
effects of IL-6 supplementation or IL-6 neutralizing antibodies
in normal and hypoplastic fetal lung explants were evaluated.
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Additionally, the potential activation of MAPK pathway by
IL-6 was investigated.
MATERIALS AND METHODS
Animal experiments were performed according to the Portuguese law for
animal welfare. Animals were housed in an accredited mouse house and
treated as specified by the recommendations of the Guide for the Care and
Use of Laboratory Animals published by the US National Institutes of Health
(National Institutes of Health Publication No.85-23, revised 1996).
Animal model and experimental design. Sprague-Dawley female rats
(225g; Charles-River, Barcelona, Spain) were maintained in appropriate cages
under controlled conditions and fed with commercial solid food. The rats were
mated and checked daily for vaginal plug. The day of plugging was defined
as gestational d 0.5 for time dating purposes. Nine and a half dpc pregnant rats
were exposed to 100 mg of nitrofen (2,4-dichlorophenyl-p-nitrophenylether)
dissolved in 1 mL of olive oil administered by gavage (nitrofen-induced
hypoplastic lungs: nitrofen group) or with an equal volume of vehicle (normal
lungs: normal group) (19). For in situ hybridization and PCR studies, normal
lungs were used, whereas for fetal lung explant cultures normal and nitrofen-
induced hypoplastic lungs were used.
From the normal group, fetuses were removed by cesarean section at 14.5,
15.5, 17.5, 19.5, and 21.5 dpc. Fetuses at 14.5 dpc were processed in toto for
whole mount hybridization studies. Fetuses older than 14.5 dpc were killed by
decapitation and lungs were excised, processed, and embedded in paraffin for
in situ hybridization. Random left lung samples were collected for the
quantification of IL-6 expression by real-time PCR. These samples were
immersed in RNAlater (QIAGEN GmbH, Hilden, Germany) and stored at
80°C.
Fetuses harvested at 13.5 dpc from normal and nitrofen groups were
dissected and lungs collected for explant culture. After 4 d culture, explants
from each group were collected either for immunohistochemistry or Western
blot analysis.
ISH studies. Digoxigenin-labeled IL-6 probe was synthesized from a 901
bp fragment of the coding sequence of IL-6, inserted on a pBluescript KS-
vector (kindly supplied by Dr. Georg H. Fey, University of Erlangen, Nurn-
berg, Germany). The plasmid was linearized with BamHI and T3 RNA
polymerase was used to synthesize the antisense riboprobe. The in vitro
transcription reaction was performed using DIG RNA Labeling Mix (Roche
Molecular Biochemicals, Mannheim, Germany), according to the manufac-
turer’s instructions.
Whole mount. Embryos were fixed overnight at 4°C in 4% paraformal-
dehyde (PFA), rinsed in 1 PBS, dehydrated through a methanol series, and
stored in 100% methanol at –20°C. Whole mount ISH was performed as
previously described (20). Embryos were visualized as whole mounts in PBT
(PBS, 0.1% Tween20) under binocular microscopy (Leica MZFLIII; Leica
Geosystems AG, Heerbrugg, Switzerland), and photographed using Sony
3CCD Color Video Camera.
Paraffin sections. Tissue sections (10 m thick) were processed for ISH as
previously described by Strahle et al. (21). ISH slides were observed and
photographed on light microscope with an Axiocam color video camera (Carl
Zeiss GmbH, Jena, Germany).
RNA extraction and reverse transcription. Total mRNA from left lung
samples of 30 fetuses (15.5 dpc, n  9; 17.5 dpc, n  7; 19.5 dpc, n  7; 21.5
dpc, n  7) was extracted using the RNeasy Mini Kit Protect (QIAGEN
GmbH). Total mRNA quantification was done by spectrophotometry (Bio-
Photometer, Eppendorf AG, Hamburg, Germany).
Reverse transcription was performed as previously described by Santos et
al. (22).
Quantitative real-time PCR. Quantitative real-timePCR was performed as
previously described by Santos et al. (22).
Primer design was based on available sequences in GenBank (NCBI-
NLM-PubMed-Gene). All the primers are intron-spanning (Table 1). For IL-6
and -actin primer sets, standard amplification curves (ST curves) were made
with randomly selected cDNA samples setting r  0.99. In all the samples
IL-6 expression was normalized for -actin.
Fetal lung explant cultures. Harvesting and dissection of 13.5 dpc lungs
was made in DPBS (Cambrex, East Rutherford, NJ) under a dissection
microscope (Leica MZFLIII). The lungs were transferred to Nucleopore
membranes with an 8 m pore size (Whatman, Clifton, NJ) and incubated in
a 12-well culture plates from Costar (Corning, NY). The membranes were
presoaked in DMEM (Cambrex) for 1 h before the explants were placed on
them. Floating cultures of the explants were incubated in 200 L of 50%
DMEM, 50% nutrient mixture F-12 (Invitrogen, Carlsbad, CA) supplemented
with 100 g/mL streptomycin, 100 units/mL penicillin (Invitrogen), 0.25
mg/mL ascorbic acid (Sigma Chemical, Poole, Dorset, UK) and 10% FCS
(Invitrogen). The fetal lung explants were incubated in a 5% CO2 incubator at
37°C for 96 h, and the medium was replaced every 48 h. The branching
morphogenesis was monitored daily by photographing the explants. At d 0
(D0: 0 h) and d 4 (D4: 96 h) of culture, the total number of peripheral airway
buds (branching) in all lung explants was determined, whereas the epithelial
perimeter was measured using AxionVision Rel. 4.3 (Carl Zeiss GmbH). The
results of branching and epithelial perimeter were expressed as D4/D0 ratio.
IL-6 supplementation studies. Twelve normal and 12 nitrofen-hypoplastic
lung explants were used as control (0 pg/mL). Additionally, recombinant rat
IL-6 (R & D Systems, Minneapolis, MN) was added daily to normal and
nitrofen-induced hypoplastic lung explants to achieve a final concentration of
0.01, 0.1, 1, 10, 100 pg/mL (normal lungs: 0.01, n  8; 0.1, n  8; 1, n  8;
10, n  10; 100, n  8. Hypoplastic lungs: 0.01, n  10; 0.1, n  9; 1, n 
9; 10, n  12; 100, n  8).
IL-6 neutralizing studies. Normal explants were treated daily with IgG
anti-rat IL-6 neutralizing antibody (n  12) at concentration of 1.0 g/mL (30
times the concentration previously shown to suppress IL-6 effect) (R & D
Systems). Nonspecific effects were evaluated by adding identical concentra-
tion of normal goat IgG control antibody (n  10) (R & D Systems).
Proliferation assay by immunohistochemistry. Nontreated (0 pg/mL) and
IL-6 treated (10 and 100 pg/mL) normal and nitrofen explants as well as
normal explants treated with normal goat IgG and IgG anti-rat IL-6 neutral-
izing antibodies (interruption studies) were processed for proliferation assay
(5 per each group). Ki-67 immunostainings were performed on formalin-fixed
and paraffin-embedded lung explants. Sections (5 m) were placed on
SuperFrost Plus slides (Menzel-Glaser, Braunschweig, Germany). The pri-
mary antibody, a monoclonal rabbit serum anti-Ki-67 (NeoMarkers, Fremont,
CA), was used in a 1:200 dilution. After dewaxing in xylene and rehydration
in ethanol, the samples were incubated in 3% hydrogen peroxide in methanol
to quench endogenous peroxidase. Antigen retrieval was achieved by boiling
in 10 mM citrate buffer followed by cool down at room temperature. Samples
were blocked with 5% BSA (Roche Molecular Biochemicals). Incubation of
the primary antibody occurred at 4°C overnight. Negative control reactions
included omission of the primary antibody. Incubation with the UltraVision
detection system anti-polyvalent horseradish peroxidase (Lab Vision Corpo-
ration, Fremont, CA) was carried accordingly to manufacturer’s instructions.
To visualize the peroxidase activities in sections, diaminobenzidine tetrahy-
drochloride was used. Sections were counterstained with hematoxylin.
For cell proliferation quantification, epithelial and mesenchymal Ki-67
positive and negative cells were counted at 20 magnification (Olympus DP
70, Cell P; Olympus, Hamburg, Germany) in four independent peripheral
areas per explant. Results are presented as percentage of the ratio of positive-
to-total cells normalized for lung section area.
Western blot analysis. Nontreated (0 pg/mL) and 10 pg/mL IL-6 treated
normal explants were processed for Western blot analysis. Proteins from lung
explants were obtained according to Kling et al. (18). Five micrograms of
protein were loaded onto 12.5% acrylamide minigels, electrophoresed at 100
V at room temperature, and then transferred to Hybond-C Extra (Amersham
Pharmacia Biotech, Inc., Piscataway, NJ). Blots were probed with p38,
p44/42 (ERK1/2), JNK, phospho-p38 (dp-p38), phospho-p44/42 (dp-ERK1/
2), phospho-JNK (dp-JNK) MAb (New England Biolabs, US) according to
manufacturer’s instructions. For loading control, blots were probed with
-tubulin MAb (Santa Cruz Biotechnology Inc., US). Afterward blots were
incubated with a secondary horseradish peroxidase conjugate (New England
Table 1. Primers used for quantitative PCR
Gene Accession number Primer set Product size (bp)
IL-6 NM_012589 5=-CAA GAG ACT TCC AGC CAG-3=
5=-CTC CGA CTT GTG AAG TGG T-3=
141
-actin NM_031144 5=-GAT TTG GCA CCA CAC TTT CTA CA-3=
5=-ATC TGG GTC ATC TTT TCA CGG TTG G-3=
114
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Biolabs, Beverly, MA), developed with Super Signal West Femto Substrate
(Pierce Biotechnology, Inc., Rockford, IL) and exposed to Hyperfilm ECL
(Amersham Pharmacia Biotech, Inc.).
Statistical analysis. All quantitative data are presented as mean  SEM.
Statistical analysis was performed by one-way ANOVA (real-time PCR and
morphometric explants studies) or three-way ANOVA (proliferation studies)
on ranks and the Student-Newman-Keuls test was used for post-test analysis.
For IL-6 neutralizing studies (morphometric and proliferation studies), t test
analysis was used. Statistical significance was set at p  0.05.
RESULTS
IL-6 expression pattern during normal pulmonary devel-
opment. ISH studies revealed that IL-6 was expressed
throughout all studied gestational ages in fetal lung (Fig. 1).
Figure 1 illustrates IL-6 mRNA predominantly expressed in
primitive lung epithelium presenting significant expression
since the earliest studied stage of rat lung development (14.5
dpc). IL-6 mRNA levels appeared highest during pseudoglan-
dular stage (14.5 and 15.5 dpc) decreasing during subsequent
stages of lung development.
Real-time PCR analysis. The ISH results of IL-6 expres-
sion prompted us to perform real-time PCR to quantify rela-
tive expression of IL-6 levels during normal lung development
(Fig. 2). The mRNA levels of -actin were not significantly
altered during gestation and were subsequently used to nor-
malize the expression data for IL-6. In Figure 2, mRNA levels
of IL-6 normalized to -actin are presented. In normal fetal
lung development, IL-6 was expressed in all studied gesta-
tional ages. IL-6 mRNA levels were significantly higher in the
earliest assessed gestational age (15.5 dpc), which corre-
sponds to the pseudoglandular stage of lung development. In
the subsequent stages of lung development, as suggested by
ISH results, IL-6 mRNA levels decreased.
IL-6 supplementation studies. To evaluate IL-6 role during
lung morphogenesis, normal and hypoplastic fetal lung ex-
plants were treated with different doses of recombinant rat
IL-6. In Figure 3, representative examples of normal (Fig. 3A)
and hypoplastic (Fig. 3B) fetal lung explants treated with
increasing IL-6 doses are illustrated. IL-6 appears to have an
enhancing effect on lung explants growth, except with the
highest dose.
The results of morphometric analysis on fetal lung explants
are summarized in Figure 4. In normal and nitrofen explants,
increasing IL-6 doses induced a biphasic effect on total num-
ber of peripheral airway buds as well as on epithelial perim-
eter. Lower IL-6 doses enhanced explant growth, whereas the
highest dose did not induce significant effect. In normal
explants (Fig. 4, A and C), IL-6 treatment induced maximal
growth rates at 10 pg/mL, whereas in nitrofen explants, the
total number of peripheral airway buds (Fig. 4B) was maximal
at 10 pg/mL and epithelial perimeter (Fig. 4D) at 1 pg/mL.
The number of peripheral airway buds and the epithelial
Figure 1. IL-6 expression pattern during normal rat lung development. ISH studies showed that in normal fetal lung, IL-6 expression was localized to the
primitive airway epithelium. The positive IL-6 signal was detected during all the studied developmental ages, predominantly during the pseudoglandular phase
(14.5 and 15.5 dpc). Scale bar: 14.5 dpc  4960 m; 15.5, 17.5, 19.5, and 21.5 dpc  100 m.
Figure 2. IL-6 mRNA levels during normal fetal rat lung development,
expressed in arbitrary units normalized for -actin (15.5 dpc: n  9; 17.5 dpc:
n  7; 19.5 dpc: n  7; 15.5 dpc: n  7). *p  0.05 vs 15.5 dpc, § p  0.05
vs 17.5 dpc, ¶ p  0.05 vs 19.5 dpc.
Figure 3. Branching morphogenesis in rat lung explant system. (A) Normal
lung explants. (B) Nitrofen-hypoplastic lung explants. Upper panel is repre-
sentative of lungs at 13.5 dpc at culture d 0 (D0). Bottom panel represents
lungs, treated with different IL-6 doses, at d 4 (D4). Scale bar  6349 m (all
images at same magnification).
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perimeter were significantly reduced in nitrofen when com-
pared with normal explants at D0 (Table 2). However, in the
absence of IL-6 treatment and after 4 d in culture no signifi-
cant differences between normal and nitrofen groups were
observed. After IL-6 treatment, D4/D0 ratio of the number of
peripheral airway buds (Fig. 4B) and epithelial perimeter
(Fig. 4D) was always higher in the nitrofen group than in the
normal group, independently of IL-6 dose.
Figure 5 shows cellular proliferation assay in normal and
nitrofen explants nontreated and treated with either 10 pg/mL
(dose of maximal effect) or 100 pg/mL (dose with lesser
effect). Treatment with 10 pg/mL of IL-6 induced a significant
increase on proliferation rate in normal and nitrofen explants,
whereas in explants treated with 100 pg/mL of IL-6 a signif-
icant decrease is evident in such proliferation when compared
with 10 pg/mL. No significant differences between normal and
nitrofen groups were observed, although there is a statistically
significant interaction between variables: groups  IL-6 doses
Figure 5. Cellular proliferation assay in normal and nitrofen explants by
Ki-67 immunohistochemistry. (A) Nontreated normal explants. (B) 10 pg/mL
IL-6 treated normal explants. (C) 100 pg/mL IL-6 treated normal explants. (D)
Nontreated hypoplastic explants. (E) 10 pg/mL IL-6 treated hypoplastic
explants. (F) 100 pg/mL IL-6 treated hypoplastic explants (five lungs ana-
lyzed per each group). The bottom graphics presents epithelial and mesen-
chymal cellular proliferation quantification. Results are expressed as percent-
age of positive-to-total cells ratio normalized for mm2. Scale bar  100 m
(all images at same magnification). *p  0.05 vs normal or nitrofen explants
nontreated, ¶ p  0.05 vs IL-6 at 10 pg/mL. ns, not statistically significant.
Figure 6. IL-6 neutralizing studies in normal lung explants treated with
normal goat IgG (control n  10) and IgG anti-rat IL-6 antibodies (n  12).
A: Branching morphogenesis (upper panel) and morphometric analysis of
lung growth (middle and bottom panels). B: Cellular proliferation assay (5
lungs analyzed per each group). Scale bar A  6349 m, B  100 m. p 
0.01: * vs. goat IgG.
Figure 4. Morphometric analysis of lung explant cultures treated with dif-
ferent IL-6 doses. (A) Number of total airway buds in normal explants. (B)
Number of total airway buds in hypoplastic explants. (C) Epithelial perimeter
in normal explants. (D) Epithelial perimeter in hypoplastic explants. Results
are expressed as D4/D0 ratio (Normal lungs: 0, n  12; 0.01, n  8; 0.1, n 
8; 1, n  8; 10, n  10; 100, n  8. Hypoplastic lungs: 0, n  12; 0.01, n
 10; 0.1, n  9; 1, n  9; 10, n  12; 100, n  8). *p  0.05 vs IL-6 at
0 pg/mL, § p  0.05 vs IL-6 at 0.01 pg/mL, † p  0.05 vs IL-6 at 1 pg/mL,
¶ p  0.05 vs IL-6 at 10 pg/mL.
Table 2. Number of peripheral airway buds and epithelial
perimeter in normal and nitrofen groups, at d 0 and 4 of culture
Group
Number of
peripheral airway buds Epithelial perimeter
D0 D4 D0 D4
Normal 6  0 54.8  4.9 7054  255 31 512  3887
Nitrofen 4.33  0.42 51.8  4.76 5046  294 29 222  3522
p Value 0.01 NS 0.01 NS
NS, not statistically significant.
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(p  0.001). Finally, no significant differences in proliferation
rate between epithelium and mesenchyme were observed.
IL-6 neutralizing studies. In Figure 6, results of morpho-
metric analysis (Fig. 6A, left panels) and proliferation studies
(Fig. 6B, right panels) in normal lung explants treated with
normal goat IgG (control) and IgG anti-rat IL-6 antibodies are
shown. IL-6 blocking antibodies significantly reduced the
number of peripheral airway buds, epithelial perimeter and
epithelial and mesenchymal cellular proliferation rate.
MAPK signaling pathway. Normal lung explants treated
with IL-6 at 10 pg/mL (dose with maximal effect), presented
(semi-quantitative analysis) an enhanced p-38 kinase phos-
phorylation when compared with nontreated explants. No
differences were observed in MEK1/2 and SAPK/JNK phos-
phorylation (Fig. 7).
DISCUSSION
This study demonstrated that IL-6 was constitutively ex-
pressed in pulmonary primitive epithelium, during all studied
gestational ages of lung development, presenting highest lev-
els of expression during pseudoglandular stage. Blocking IL-6
significantly reduced branching and cellular proliferation rate
in normal explants, whereas IL-6 supplementation, either in
normal or hypoplastic fetal lung explants, induced a biphasic
effect on branching and cellular proliferation rate, with in-
creased effect at lower doses, while no additional effect was
obtained with the highest dose. These effects of IL-6 are most
likely mediated through MAPK signaling pathway via p38.
IL-6 is a multifunctional inflammatory cytokine with im-
portant roles in cell proliferation, differentiation, growth, and
apoptosis (2–4). Several clinical and experimental studies
have investigated IL-6 role in pathophysiology of different
lung diseases. In the adult, IL-6 has a critical role on inflam-
matory pathogenesis of acute respiratory distress syndrome
(23), asthma (24), chronic obstructive pulmonary disease (25),
and non-small-cell lung cancer (26). IL-6 role during prenatal
and neonatal period has been studied since decreased risk of
respiratory distress syndrome in preterm neonates was dem-
onstrated (10,11). In fact, it has been proved that inflammatory
mediators, namely IL-6, promote fetal lung maturation by
inducing SP-A expression and protein synthesis consequently
improving lung mechanics and gas exchange (10,11). Studies
carried on different animal models of intra-amniotic inflam-
mation corroborated these observations in neonates exposed to
chorioamnionitis (12–15,27,28).
Pulmonary development is a complex process involving
two different cellular phenomena, growth and maturation (1).
All previous studies concerning the effect of IL-6 on prenatal
lung development had focused mainly in maturation processes
in a pathologic inflammatory context (11–15,27,28). In this
study, however, it was demonstrated that IL-6 was constitu-
tively expressed in normal primitive lung epithelium through-
out the studied ages. Interestingly, the epithelial IL-6 expres-
sion is in agreement with the findings previously documented
in adult lung (29). In adults, epithelial expression was also
observed in other branching organs such as salivary glands
(30), prostate (8,9), and mammary gland (7). However, IL-6
expression in fetuses was only described during submandib-
ular gland morphogenesis (5,6). In fact, Melnick et al. (5)
showed a significant increase in IL-6 mRNA with progressive
salivary gland development. Conversely, the current study
demonstrated that in fetal lung the highest IL-6 mRNA levels
occurred during early pseudoglandular stage decreasing pro-
gressively in subsequent stages of lung development.
Hypothesizing that IL-6 has a role during lung branching
morphogenesis, normal fetal lung explants were cultured with
increasing doses of IL-6 or with IL-6 neutralizing antibodies.
Furthermore, IL-6 effect in nitrofen-induced hypoplastic lungs
was also studied since it is well established that these lungs
have restricted branching (31,32). This work clearly demon-
strated that IL-6 supplementation induced a biphasic pattern
on branching either in normal or hypoplastic explants. In fact,
lower doses of IL-6 induced an increase in growth rate (total
number of peripheral airways buds and epithelial perimeter) of
normal and hypoplastic lung explants, whereas highest dose
did not accomplish additional effect. These observations were
corroborated by proliferation studies, which demonstrated that
10 pg/mL of IL-6 (maximal effect on branching) significantly
increased Ki-67 epithelial and mesenchymal positive cells. On
the other hand, 100 pg/mL of IL-6 induced no significant
changes in proliferation rate when compared with nontreated
explants. Interestingly, it seems that IL-6’s effects were exac-
erbated in nitrofen explants. Although nitrofen explants are
smaller at D0, after 4 d in culture, no significant differences
between normal and nitrofen explants could be detected (Ta-
ble 2). The ability of hypoplastic explants to grow in culture
with higher rates than normal explants had already been
previously observed (33), however, the explanation for this
phenomenon remains to be elucidated. A possible explanation
consists in hypoplastic lungs eliciting up-regulation of some
effectors as documented for neuroendocrine cellular products
(33). Interestingly, it was also reported that end-gestation
Figure 7. MAPK activities in nontreated (1) and treated with IL-6 at 10
pg/mL (2) lung explants. Western blot analysis of MAPK with MAbs to p38,
ERK1/2 and JNK1/2 (A) and to diphosphorylated forms of p38 (dp-p38), ERK1/2
(dp-ERK1/2) and SAPK/JNK (dp-JNK1/2) (B). Control loading was performed
using -tubulin (55 KDa). ERK1 and 2 correspond to 44 and 42 KDa, respec-
tively. JNK1 and 2 correspond to 46 and 54 KDa, respectively.
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human hypoplastic lungs present higher production of tumor
necrosis factor- than normal lungs (34).
Regarding the biphasic pattern of IL-6 effects on branching
rate, it is interesting to stress that previous studies relating
inflammation, lung maturation, and incidence of respiratory
distress syndrome (RDS) report a similar pattern. In fact,
although intrauterine infection seems to protect very prema-
ture infants against RDS, high quantities of pro-inflammatory
cytokines cause serious disease (35). On the other hand, our
findings suggest that IL-6 is constitutively produced during
the earliest gestational stages, which may contribute for the
explanation of enhanced fetal lung tolerance to inflammation
during early gestation when compared with later gestation (26).
Although IL-6 knockout mice do not seem to have signif-
icant lung development abnormalities (36–38), this study
clearly suggests a physiologic role of IL-6 in lung branching
morphogenesis. Although previous studies on IL-6 and lung
development emphasized maturational process, the highest
expression of IL-6 on the early fetal lung development stages
suggests that the physiologic role for IL-6 is most likely linked
to branching.
Previous reports demonstrated epithelial expression of
functional IL-6 receptor during fetal lung development (4,39).
The mechanism responsible for IL-6 enhancing effects during
lung branching morphogenesis is most likely dependent on
gp130 signaling pathway through Stat3 and/or MAPK (2–4).
In fact, it seems that IL-6 signaling through Stat3 is important
to normal submandibular gland morphogenesis in the mouse
(5) as well as in human prostate cancer cell growth (40).
Additionally, adult rat mammary gland remodeling depends
on gp130 signaling through Stat3 and MAPK (7). None of the
previous studies implied JAK/STAT signaling pathway in
fetal lung growth mechanisms. In contrast, MAPK signaling
was recently suggested as a crucial pathway for fetal lung
development (18). Thus, MAPK pathway activation by IL-6 in
fetal lung development was investigated. Explants treated with
10 pg/mL IL-6 were selected due to its maximal effect on
growth. These experiments clearly show activation of p38-
MAPK by IL-6 treatment, whereas no significant activation of
MEK1/2 and JNK pathways was observed.
In conclusion, IL-6 epithelial expression throughout fetal
lung development as well as the present in vitro studies
suggest a physiologic role for endogenous IL-6 on pulmonary
branching mechanisms most likely involving p38-MAPK in-
tracellular pathway.
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